Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini. The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2. The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial. The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data. The panel discussed the latest updates in NMIBC, including relevant data pertaining to pembro, atezo, and more. The panel discussed the latest data and updates in frontline bladder cancer during a livestreamed session. Drs. Dorff and Agarwal share how crucial it is for mPC patients around the world to undergo germline or somatic testing. Drs. Hope and Agarwal provide an overview of the SOC for 1L mCRPC prior to TALAPRO-2 and how the SOC has since changed. Drs. Dorff and Agarwal summarize the toxicities associated with talazoparib for patients with metastatic CRPC. Drs. Dorff and Agarwal discuss the goals of the TALAPRO-2 study and further understandings that subset analyses provided. Drs. Powles and Nizam discuss her strategy of intensifying treatment upfront in oligometastatic urothelial carcinoma. Drs. Powles, Tawagi, and Berg highlight attempts to define 2L SOC options, as well IO rechallenging in bladder cancer. Drs. Rini, Barata, and Hamid discuss takeaways from the session, including trial design and unmet needs in the field. Dr. Pedro Barata discusses his thoughts on the use of cisplatin in patients with bladder cancer, as well as CheckMate 901. Dr. Vadim Koshkin gives his thoughts on the CheckMate 901 study and its data that were presented at the conference. Dr. Petros Grivas discusses new bladder cancer data, including the TAR-200 delivery system and the SunRISe trials. Patient advocate Mary Beth Ballard discusses how new research and data gives hope to patients with bladder cancer. Dr. Gautam Jayram discusses his biggest takeaways from the event, including panels on non-muscle invasive bladder cancer. Amanda Nizam, MD, discusses her proposed trial examining EV and pembrolizumab in patients with oligometastatic UC. Dr. Regina Barragán-Carrillo discusses new data in the IO-refractory RCC setting that were presented during the RCC panel.